Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Importance of "Clinical Mind" Stressed: JASDI Forum
January 30, 2006
- Chugai: Sales Up 11%, Profits Up 57.2%
January 30, 2006
- PI Study on Nanoplatin Approved in UK: NanoCarrier
January 30, 2006
- MCHC to Aim at Fusion of Pharmaceuticals and Diagnostics
January 30, 2006
- 3 Major DDS Preparations under Development by LTT Bio-Pharma
January 30, 2006
- Sankyo, Daiichi to Collaborate in Marketing 2nd Product
January 30, 2006
- Takeda Enters PII for the Anti-obesity Drug ATL-962 in Japan
January 30, 2006
- AMO to Focus on the Vision Care Life Cycle
January 30, 2006
- PHARMA DELEGATES
January 30, 2006
- NEW PRODUCTS
January 30, 2006
- PhRMA Announces Mr Ira Wolf as New Japan Representative
January 30, 2006
- REGULATORY NEWS IN BRIEF
January 30, 2006
- Early Approval of 4 Products Urged by Council
January 30, 2006
- Gaps Remain in Participation of Joint-stock Companies in Medical Services
January 30, 2006
- Outline of FY2006 Medical Fee Revision Approved by Chuikyo
January 30, 2006
- Nichi-iko to Make 108 GE Drugs Available in All Specifications
January 30, 2006
- Original and Generic Drugs "Not Bioequivalent": Prof. Masada
January 30, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 30, 2006
- Chuikyo Recommends Replacement of Current Prescription Form
January 30, 2006
- Josai Clinic Provides Comprehensive Care for Hair Loss
January 30, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…